Hematopathology Diagnosis

Pittaluga博士和我帮助诊断和分类反应性和肿瘤性淋巴增生性疾病，免疫缺陷状态和各种血液恶性肿瘤。我们为NCI的医生以及其他研究所（特别是NIAID，NHLBI，NHGRI和NIAMSD）研究血液淋巴疾病患者的医生提供咨询和合作服务。我们定期出席由NCI和其他研究所（NIAID，NHLBI和NHGRI）的临床分支机构主办的会议。我们每年收到2000多起咨询案件。我们努力将咨询限制在困难或具有挑战性的案件，不接受“例行第二意见”。很大一部分病例（约20%）是由其他学术机构基于诊断不确定性或由于几个机构之间的意见分歧而提交的。我们通常是具有挑战性的诊断问题的最终仲裁者。此外，我们还根据我们的临床实践进行了新的观察，一些出版物来自最初在咨询中审查的病例材料。我们的临床咨询实践也与其他NIH临床小组协同，提高转诊到NIH临床协议。我们的工作改善了几种罕见疾病的诊断和分类，包括多中心Castleman病，KSHV和EBV相关的增殖，B细胞和T细胞淋巴瘤的新形式，以及组织细胞肿瘤的扩展谱。我们已经帮助确定了成人淋巴瘤与儿童淋巴瘤之间的差异。我们已经研究了淋巴结和淋巴结淋巴瘤之间的差异。这项工作推进了我们的知识，关于淋巴和组织细胞肿瘤的分类。

Dr. Pittaluga and I aid in the diagnosis and classification of reactive and neoplastic lymphoproliferative disorders, immunodeficiency states, and diverse hematological malignancies. We provide consultative and collaborative services to physicians in the NCI, as well as to physicians studying patients with hematolymphoid disorders in other institutes, in particular NIAID, NHLBI, NHGRI, and NIAMSD. We regularly present at conferences sponsored by clinical branches in the NCI and other Institutes (NIAID, NHLBI, and NHGRI.) We receive more than 2000 cases in consultation each year. We try to restrict consultations to difficult or challenging cases, and do not accept cases for "routine second opinions". A significant proportion (approximately 20%) of the cases are submitted by other academic institutions based on diagnostic uncertainty, or because of differences of opinion among several institutions. We are often the final arbiter on challenging diagnostic problems. Additionally, we have made novel observations based on our clinical practice, and a number of publications have emanated from case material originally reviewed in consultation. Our clinical consultation practice also synergizes with other NIH clinical groups, enhancing referral to NIH clinical protocols. Our work has led to improvement in the diagnosis and classification of several rare diseases including multicentric Castleman disease, KSHV- and EBV-associated proliferations, novel forms of both B-cell and T-cell lymphoma, and expanding spectrum of histiocytic neoplasms. We have helped to define the differences between lymphomas occurring in adults from those in the pediatric age group. We have studied the difference between nodal and extranodal lymphomas. This work has advanced our knowledge regarding the classification of lymphoid and histiocytic neoplasms.